Category Archives: Interventional Cardiology

November 14, 2019 There were positive results in the TANGO Trial is a phase 2, dose escalation, double-blinded trial comparing the delivery of temsirolimus to saline control in patients with severe claudication or critical limb ischemia. This is the first United States trial to investigate a sirolimus analog to improve the durability of peripheral revascularization procedures Continue reading →

November 14, 2019 A new study from researchers at the Smidt Heart Institute at Cedars-Sinai shows that electronic nicotine delivery systems, including devices such as e-cigarettes, may be just as harmful to the heart, if not more, than traditional cigarettes. The findings were presented today at the annual American Heart Association Scientific Sessions 2019 Continue reading →

The fresh report was added to Reportocean.com offering. Click here for more information @https://www.reportocean.com/industry-verticals/details?report_id=26940 This ready to use report offers you detailed insight into the global interventional cardiology and peripheral vascular devices industry with market size, in value terms, estimated at USD million/billion for the period. It also provides the projected growth rate for the next 5 to 6 years along with forecast market value Continue reading →

The Global Interventional Cardiology Market, Size, Share, Outlook and Growth Opportunities 2019-2026 presents a comprehensive analysis of the countries Interventional Cardiology. Key trends and critical insights into Global Interventional Cardiology market along with key drivers, restraints, and growth opportunities are present in the report Continue reading →

With rise in pollution the citizens of Delhi are facing many complications. Continue reading →

November 14, 2019 Results were positive for the multicenter PROMISE I Trial represents the first human use in the United States of a purpose-built percutaneous deep vein arterialization system for the treatment of no-option chronic limb-threatening ischemia (CLTI) patients. Data was presented at the 2019 Vascular Interventional Advances (VIVA) annual meeting. The LimFlow procedure permanently bypasses unreconstructable arteries and leverages healthier veins as a conduit to create new routes to perfuse tissue in the foot Continue reading →

Global Vascular Closure Devices Marketwas valued US$ 705 Mn in 2017 and is expected to reach US$ 1286.5 Mn by 2026, at a CAGR of 7.81 % during a forecast period. The vascular closure devices market is segmented into product, end user, access, hole size, and region.In terms of product, vascular closure devices market is segmented into passive approximators and active approximators. Continue reading →

Opsens Inc. (TSE:OPS) Analysts at M Partners issued their FY2021 earnings per share (EPS) estimates for Opsens in a note issued to investors on Friday, November 15th. M Partners analyst A Continue reading →

November 15, 2019 Results from the MARVEL 2 (Micra Atrial Tracking Using A Ventricular accELerometer) study shows that an investigational set of algorithms in the Medtronic Micra Transcatheter Pacing System (TPS) significantly improves synchrony and cardiac function in patients with atrioventricular (AV) block. Continue reading →

Irhythm Technologies (NASDAQ:IRTC) and ABIOMED (NASDAQ:ABMD) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership. Profitability This table compares Irhythm Technologies and ABIOMEDs net margins, return on equity and return on assets Continue reading →